Device for immune regulation, brain detoxification, and cognitive protection through electromagnetic therapy

Transcranial and peripheral electromagnetic therapies effectively modulate cytokine levels and enhance lymphatic drainage to address immune dysfunction in Alzheimer's disease, improving cognitive function and reducing toxic protein accumulation.

JP7578720B2Active Publication Date: 2024-11-06NEUROEM THERAPEUTICS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2022566363
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-05-01
Publication Date
2024-11-06
Estimated Expiration
2040-05-01

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases like Alzheimer's disease, which involve immune dysfunction, have not effectively addressed the imbalance of cytokines in the immune system, leading to uncontrolled inflammation or underactivation, and there is no effective way to reverse or slow cognitive decline.

Method used

Transcranial electromagnetic therapy (TEMT) and peripheral electromagnetic therapy (PEMT) are used to modulate cytokine levels, enhance lymphatic drainage, and clear toxic proteins from the brain, thereby addressing immune dysfunction and cognitive impairment.

Benefits of technology

These therapies normalize cytokine levels, enhance lymphatic drainage, and reduce toxic protein accumulation, providing significant therapeutic benefits for cognitive function and potentially preventing or reversing disease progression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578720000001
    Figure 0007578720000001
  • Figure 0007578720000002
    Figure 0007578720000002
  • Figure 0007578720000003
    Figure 0007578720000003
Patent Text Reader

Abstract

In one example, the present disclosure describes a method for normalizing cytokine levels in a subject's bloodstream. According to the method, an array of electromagnetic emitters is positioned near the subject. An electromagnetic wave generator generates an electromagnetic field having a predetermined frequency. Cytokine levels are normalized in the subject's bloodstream by applying the electromagnetic field to the subject through the electromagnetic emitters.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] 2. Background of the Invention There are several human diseases / infections that result in a dysfunction of the body's immune system. This immune dysfunction or dysfunction can be a major component to the disease / infection process and symptoms or the body's main response to the disease / infection. Furthermore, immune dysfunction associated with various diseases / infections can affect not only peripheral tissues (e.g., rheumatoid arthritis, COVID-19, asthma) but also the brain (e.g., Alzheimer's disease, multiple sclerosis, post-operative cognitive dysfunction). With regard to immune dysfunction of the human brain, the blood flowing through the dense vasculature of the brain contains white blood cells (WBCs) - the "regulators" or "effectors" of the immune system - that secrete a variety of cytokines. Similarly, microglia and astrocytes in the brain parenchyma secrete cytokines that affect brain function. [Background technology]

[0002]

[0002] Meningeal lymphatic vessels on the surface of the human brain and lymphocytes within these vessels represent a direct link between the immune system and brain function / dysfunction. These meningeal lymphatic vessels drain brain toxic substances such as aggregated beta-amyloid (Aβ) and tau from the brain.

[0003]

[0003] As a neurodegenerative brain disease involving immune system dysfunction, Alzheimer's disease (AD) devastatingly affects as many as 6 million Americans, with an additional 5 million Americans having a precursor to AD called mild cognitive impairment (MCI). Globally, AD affects tens of millions, if not hundreds of millions, of people. Currently, there is no way to reverse, halt, or even slow the progressive cognitive decline of AD. AD is the sixth leading cause of death in the United States, costs the U.S. government $200 billion annually, and has the potential to compromise the U.S. healthcare system by 2050 if no effective treatment or prevention is found. Despite billions of dollars spent trying to find drugs or biologics to treat AD, clinical trials involving over 150 drugs or biologics to treat or prevent the disease have been disappointing so far. Summary of the Invention [Means for solving the problem]

[0004]

[0004] Thus, "non-pharmacological" approaches to the disease have emerged and have been or are currently undergoing clinical trials in AD subjects. These neuromodulation approaches include magnetic stimulation (tMS), transcranial direct current stimulation (tDCS), and deep brain stimulation (DBS). All three of these approaches stimulate the activity of neurons in the brain. However, as with pharmaceuticals and biologics, none of these approaches have shown to date any improvement in cognitive function in AD subjects or any impact on the AD process. Two new neuromodulation approaches (transcranial photomodulation and transcranial ultrasound therapy) have just begun clinical trials for AD. Collectively, these five neuromodulation approaches have not been seen to address immune dysfunction in AD, specifically as defined by abnormal blood levels of both inflammatory and non-inflammatory cytokines.

[0005] BRIEF DESCRIPTION OF THE DRAWINGS

[0005] The accompanying drawings illustrate various examples of the principles described herein and are a part of this specification. The illustrated examples do not limit the scope of the claims. [Brief description of the drawings]

[0006] [Figure 1] 1 is a block diagram of an electromagnetic treatment device according to an example of the principles described herein. [Diagram 2]

[0007] 1 is a flow chart of a method for normalizing cytokine levels in the bloodstream of a subject, according to an example of principles described herein. [Diagram 3]

[0008] 1 is a flow chart of a method for normalizing cytokine levels in the bloodstream of a subject, according to another example of principles described herein. [Figure 4]

[0009] 1 is a flow chart of a method for modulating AD markers in the bloodstream of a subject, according to an example of principles described herein. [Diagram 5]

[0010] 1 is a flowchart of a method for treating cognitive impairment via electromagnetic therapy according to an example of principles described herein. [Figure 6A]

[0011] 1 illustrates transcranial electromagnetic therapy (TEMT) to the head according to an example of principles described herein. [Figure 6B]

[0011] FIG. 1 illustrates transcranial electromagnetic therapy (TEMT) to the head according to an example of the principles described herein. [Figure 6C]

[0011] FIG. 1 illustrates transcranial electromagnetic therapy (TEMT) to the head according to an example of the principles described herein. [Figure 7A]

[0012] 6B shows the arterial blood vessels in the human brain and their proximity to electromagnetic field emitters positioned on the head surface in the example of FIG. 6A. [Figure 7B]

[0013] It shows the arterial vessels on the surface of the human brain and how the emitters in the example of FIG. 6A are also in close proximity to those extracranial vessels. [Figure 8A]

[0014] FIG. 1 shows the effect of 2 months of daily TEMT on blood levels of eight cytokines before (baseline) and after (day 60) an individual Alzheimer's patient underwent 2 months of daily TEMT. [Figure 8B]

[0015] The effect of 2 months of daily TEMT on blood levels of two of the cytokines shown in FIG. 8A (IL-17a and IL-18) is shown, except that the mean and SEM for each of the two groups are presented. [Figure 9]

[0016] FIG. 1 shows the effect of a single 2-hour TEMT session on blood levels of four cytokines before (baseline) and after 1 hour of TEMT in Alzheimer's patients. [Figure 10]

[0017] 1 shows meningeal lymphatic vessels in the human brain that appear to remove brain toxins by draining lymph to the deep cerebral lymph nodes. [Figure 11A]

[0018] Illustrates the lymphatic system within the upper body of the human body. [Figure 11B]

[0019] In particular, peripheral electromagnetic therapy (PEMT) is shown in which electromagnetic field emitters are placed over major arteries, veins, and lymphatic vessels in the axial region of the neck and arms. [Figure 12A]

[0020] Using the same baseline and day 60 blood samples from AD subjects analyzed for the eight cytokines graphed in Figures 8A and 8B, the effect of 60 days of TEMT on blood t-tau levels from individual AD subjects is shown. [Figure 12B]

[0021] FIG. 12A shows the effect of TEMT for 60 days on blood tau levels as mean±SEM in each of the two groups of AD subjects shown in Cooke. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007]

[0022] The presented figures provide examples and / or embodiments consistent with the methods described in this provisional application, however, the description is not limited to the examples and / or embodiments shown in the figures.

[0008] Detailed Description of the Invention

[0023] Although there is a general consensus among AD researchers that the immune system plays a key role in AD pathogenesis, there is disagreement as to whether the progression of AD involves an overactivation (high blood cytokine levels) or underactivation (low blood cytokine levels) of the immune system. Some AD researchers believe that AD is caused at least in part by inflammation in the brain (neuroinflammation) and that administering drugs to reduce high cytokine levels in the brain's vasculature may be therapeutic, whereas others believe that AD involves a "underactive" immune system and thus that subjects' low cytokine levels predispose them to AD. In this situation, AD subjects with underactive immune systems require treatment to activate (increase) cytokine secretion by WBCs.

[0009]

[0024] In either overactivation or underactivation, the blood cytokine levels of the immune system are abnormal.Therefore, this specification presents a system and method that addresses the immune (cytokine) dysfunction of AD and the immune imbalance of a host of other peripheral and brain diseases in which immune (cytokine) imbalance is central to pathogenesis.In these situations, the method that can adjust / regulate blood cytokines back to normal or near-normal levels can lead to significant improvement of disease symptoms and possibly prevent or reverse disease progression.

[0010]

[0025] Transcranial electromagnetic therapy (TEMT) is a promising neuromodulatory approach for AD. Comprehensive preclinical studies in AD transgenic mice have shown that TEMT can reach the brain and its neurons and "disaggregate" small intraneuronal aggregates / oligomers of two toxic proteins - Aβ and tau - that appear to be the root cause of AD. These actions of TEMT, combined with its ability to enhance mitochondrial function in neurons, appear to play a role in the consistent cognitive benefits provided by TEMT in AD transgenic mice.

[0011]

[0026] To translate these findings into clinical trials in human AD subjects, the MEMOREM™ device provides whole forebrain therapy with electromagnetic fields through induction of electromagnetic fields in the brain through multiple emitters distributed on the surface of the human head. As an example of a device that provides EM fields to the brain, the MEMOREM™ device has been shown to provide substantial cognitive benefits to AD subjects, altering Aβ levels in the cerebrospinal fluid (CSF) consistent with Aβ disaggregation in the brain, and providing evidence of enhanced brain function in functional magnetic resonance imaging (fMRI) scans. Thus, devices such as MEMOREM™ that provide electromagnetic field therapy to the brain can provide significant therapeutic benefits. This specification describes various methods of applying electromagnetic field therapy to benefit the human brain and body in various ways. The contents of this specification are arrived at from "human" studies (not from in vitro or animal studies) and therefore should have direct applicability to humans.

[0012]

[0027] Thus, the present specification provides a method to 1) provide immune modulation to both the body and brain as defined by a decrease in high cytokine levels in the blood and / or an increase in low cytokine levels in the blood, 2) increase the removal of toxins from the brain through enhanced brain lymphatic drainage, 3) modulate blood markers of AD in the same direction as the ability to modulate blood cytokines, 4) protect against or treat cognitive impairment resulting from being on a ventilator and / or being hyperoxia for extended periods of time, and 5) protect against post-operative cognitive dysfunction or cognitive impairment / brain fog following surgery using anesthesia.

[0013]

[0028] This specification describes two methodologies that can address a variety of conditions to improve normal human health. Specifically, the first method is provided to treat the human brain with electromagnetic fields through transcranial electromagnetic therapy or TEMT. The second method provides electromagnetic fields to the body or periphery through peripheral electromagnetic therapy or PEMT. The use of these two bioengineering methodologies in each of multiple medical fields is described herein.

[0014]

[0029] These areas range from immune modulation, removal of toxic proteins from the brain, changes in blood cytokines associated with changes in AD markers, and resolution of immune and cognitive complications resulting from viral / bacterial infections and surgery with anesthesia. The methods described herein provide such immune modulation, enhancing the clearance of toxic proteins from the brain and inducing parallel changes in blood immune and AD markers, reducing both immune and cognitive complications that may result from viral / bacterial infections and surgery with anesthesia. Thus, the TEMT and PEMT methodologies herein may provide beneficial effects to humans, leading to a return to a healthy state.

[0015]

[0030] Referring now to the figures, Figure 1 is a block diagram of an electromagnetic therapy device (100) according to one example of the principles described herein. Specifically, Figure 1 shows an electromagnetic therapy device (100) including an array of electromagnetic emitters (102). The electromagnetic emitters (102) may be positioned adjacent to a subject's head surface, for example in a transcranial electromagnetic therapy (TEMT) device (100). In another example, the electromagnetic emitters (102) are positioned adjacent to a subject's body surface, for example in peripheral electromagnetic therapy (PEMT). The electromagnetic emitters (102) project a frequency electromagnetic field toward the patient's head and / or body. The electromagnetic emitters (102) are activated to apply an electromagnetic field / treatment to the patient, primarily for the treatment of diseases or conditions of immune system imbalances in which blood cytokine levels are abnormally high or low, but also to induce other potentially beneficial effects.

[0016]

[0031] In one example, electromagnetic waves may be generated by an electromagnetic wave generator (108), sent to an emitter (102), and then passed to tissue as an electromagnetic field. The electromagnetic treatment device (100) may include a control interface (104), a controller (106), an electromagnetic wave generator (108), and one or more electromagnetic emitters (102) that apply treatment to a desired portion of the brain or body.

[0017]

[0032] The controller (106) manages the treatment and its parameters by operating the electromagnetic wave generator (108) and the electromagnetic emitters (102) according to the prescribed treatment. The control interface (104) allows the patient or caregiver to start / stop the treatment and view the treatment status. The electromagnetic treatment device (100) can be portable, so that treatment can be applied while the patient is moving, or it can be stationary, so that the patient can receive treatment when properly positioned relative to the electromagnetic treatment device (100). The electromagnetic emitters (102) may be activated one at a time by the controller (106), or several electromagnetic emitters (102) may be activated to generate electromagnetic (e.g., radio frequency) field combinations that together generate controllable patterns at desired locations on the patient.

[0018]

[0033] As described in more detail below, the electromagnetic therapy device (100) provides: 1) immunomodulation / immunomodulation to lower or raise blood cytokine levels towards normal; 2) removal of toxic substances from the brain by enhancing clearance from the brain; 3) ability to modulate blood Alzheimer's markers in the same direction as the ability to modulate blood cytokine levels; 4) ability to protect against or treat cognitive impairment that may result from being on a ventilator and / or having higher than normal oxygen for extended periods of time; and 5) reduction or elimination of post-operative cognitive impairment / brain fog or cognitive impairment following surgery using anesthesia.

[0019]

[0034] 2 is a flow chart of a method (200) for normalizing cytokine levels in a subject's bloodstream according to one example of principles described herein. According to the method (200), an array of electromagnetic emitters (FIG. 1, 102) is positioned in proximity to the subject (Block 201). As mentioned above, such placement may be adjacent to a head surface or adjacent to a body surface of the subject.

[0020]

[0035] An electromagnetic wave generator (FIG. 1, 108) then generates an electromagnetic field (block 202). In some examples, the electromagnetic field waves have a frequency between 1 megahertz (MHz) and 430 gigahertz (GHz), a power level between 0.1 and 8 watts per kilogram (W / kg) average specific absorption rate (SAR), and a pulse repetition rate between 1 and 300 Hertz.

[0021]

[0036] The method (200) also includes normalizing cytokine levels (block 203) by applying an electromagnetic field to the subject through an electromagnetic emitter (FIG. 1, 102). In certain examples, cytokine levels are normalized in blood vessels, lymphatic vessels, and brain tissue below the emitter. In some examples, the treatment session may have a specified duration, e.g., minutes to hours. The treatment session may be repeated at predetermined intervals over a longer period of time, such as a month or years, e.g., multiple times a day, multiple times a week, etc. In other examples, the treatment may continue for days, weeks, months, or years.

[0022]

[0037] Many diseases / conditions involve a dysfunction / imbalance of the immune system - specifically as defined as a dysfunction / imbalance in the blood levels of various cytokines. In some of these diseases / conditions, the immune system is "overactive" such that there are higher than normal levels of cytokines in the blood. In this example, normalizing cytokine levels (block 203) involves lowering cytokine levels. Diseases / conditions in which an overactive immune system is clearly implicated include Alzheimer's disease, bacterial or viral infections (e.g., COVID-19, Ebola, SARS, certain influenza), rheumatoid arthritis, multiple sclerosis, Parkinson's disease, arterial hypertension, autoimmune diseases, psoriasis, depressive cognitive impairment, allergies, asthma, celiac disease, glomerulonephritis, hepatitis, inflammatory bowel disease, Crohn's disease, osteoarthritis, fibromyalgia, cardiovascular diseases (e.g., atherosclerosis), cancer, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease, systemic lupus erythematosus, and metabolic syndrome.

[0023]

[0038] Other diseases / conditions have an underactive immune system that is associated with low blood cytokine levels. In this example, normalizing the cytokine levels (block 203) includes increasing the cytokine levels. These diseases / conditions include Alzheimer's disease (whether an overactive or underactive immune system is involved is unclear), AIDS, traumatic brain injury (TBI), and chronic widespread pain.

[0024]

[0039] With respect to Alzheimer's disease (AD), the disease may involve uncontrolled brain inflammation (neuroinflammation) or systemic inflammation that may be responsible for at least some of the disease progression from mild cognitive impairment (MCI) to the various stages of AD. However, the reverse may also be true - i.e., an overactive brain and / or body's immune system and the resulting inability to resist AD pathology may play a role in the conversion of MCI to AD, followed by progressive cognitive impairment due to an overactive immune system. In either case, the method (200) modulates blood cytokine levels toward normal blood levels, which may include lowering brain inflammation in AD or upregulating cytokine levels to resist the disease. Such a method (200) may also beneficially raise cytokine levels above normal and aid in the treatment of many of the diseases / conditions involving immune imbalance listed above.

[0025]

[0040] In light of the above, the present specification describes a method (200) of providing an “electromagnetic field / treatment” to the brain (TEMT) or body (PEMT) that results in therapeutic immune regulating effects on blood circulating in the brain or body by increasing blood cytokine levels if they are too low, or decreasing blood cytokine levels if they are too high.

[0026]

[0041] In summary, in a first example addressing blood level imbalances of various cytokines, the method (200) includes generating an electromagnetic field and radiating the electromagnetic field treatment across the patient's skull and into the brain using an electromagnetic treatment device (Fig. 1, 100) employing an electromagnetic wave generator (Fig. 1, 108) and a head-cabled radiating emitter (Fig. 1, 102). The electromagnetic treatment device (Fig. 1, 100) provides in-home electromagnetic wave treatment while allowing near-total mobility. Such an electromagnetic treatment device (Fig. 1, 100) may include a custom printed circuit board (controller (Fig. 1, 106)) powered by a rechargeable battery. The electromagnetic treatment device (Fig. 1, 100) in one example provides whole-forebrain TEMT through an arrangement of eight dedicated electromagnetic emitters (Fig. 1, 102) integrated into a two-layer head cap. In this example, these electromagnetic emitters (FIG. 1, 102) may be activated sequentially, with only one electromagnetic emitter (FIG. 1, 102) being activated at any given time. When activated, the electromagnetic emitters (FIG. 1, 102) project an electromagnetic field into the brain. In this example, computer simulations show that the electromagnetic field easily penetrates the skull, then the underlying cerebral cortex, and finally to deep subcortical brain sites. For therapeutic purposes, the electromagnetic field is defined as consisting of electromagnetic waves received by the electromagnetic emitters (FIG. 1, 102), which then propagate the electromagnetic field through the air and then to some extent into the body of the patient being treated.

[0027]

[0042] The above-mentioned electromagnetic device (Fig. 1, 100) provides electromagnetic treatment not only to neurons and glial cells that constitute the cellular part of the brain, but also to cerebral blood vessels on the brain surface and deep cerebral blood vessels located in or under the cerebral cortex. That is, the area under the electromagnetic emitter (Fig. 1, 102) includes the neurons, glial cells, and cerebral blood vessels of the brain. Therefore, the cellular components of the blood (especially lymphocytes) circulating in those cerebral blood vessels can be affected by the electromagnetic field emitted from the electromagnetic emitter (Fig. 1, 102) positioned on the head surface.

[0028]

[0043] In a clinical study in which TEMT was administered to mild / moderate AD subjects through such a TEMT device, blood samples were taken at baseline, after the first 1-hour treatment, and after 1-hour treatment twice daily for 60 days. Analysis of plasma for a panel of eight cytokines (GCSF, GMCSF, PDGF, VEGF, IL-10, IL-15, IL-17A, and IL-18) revealed a clear immune system-modulating ability of TEMT. Especially when baseline cytokine levels were low (below normal), 60 days of TEMT usually increased cytokine levels to at least normal levels. Conversely, when blood cytokine levels were high (above normal), TEMT induced a reduction to near-normal or normal levels. These results have profound implications since diseases / conditions characterized by an overactive immune system could be reactivated by TEMT such that in the case of AD, the reactivated immune system could block or prevent AD pathogenesis. A similar but reversed situation can be envisaged for diseases / conditions characterised by an overactive immune system.

[0029]

[0044] In the same clinical study, analysis of cytokine levels after only 1 hour of TEMT revealed already occurring therapeutic changes in the same direction as those seen after 60 days of treatment. Baseline cytokine levels (below or above normal) universally predicted treatment response - always toward normal levels for all subjects and all cytokines, even after this one treatment. Activation or suppression of regulatory T cells by TEMT could be one possible explanation for this rapid cytokine response to TEMT. It is hypothesized that such profound immune-modulating capabilities of electromagnetic fields are evident in individuals with or without diseases / conditions involving immune dysfunction.

[0030]

[0045] As a more specific example of addressing imbalances in blood levels of various cytokines, the TEMT methodology can be used against an overactive immune system in AD. Two cytokines that play a role in brain cognitive function (GCSF and GMCSF) are often significantly reduced in the blood of AD subjects. By raising the blood levels of these cytokines to normal or higher than normal levels, the electromagnetic field can indirectly induce beneficial modifications to the cognitive sites of the brain. Thus, normalizing blood cytokine levels (block 203) can include enhancing secretion of GCSF and GMSCF cytokines from circulating white blood cells. This can be done by applying an electromagnetic field to the subject via an electromagnetic emitter (Figure 1, 102).

[0031]

[0046] Doing so may affect certain brain components. That is, raising cytokine levels from lower than normal to normal (block 203) may include raising the number of microglial (immune) cells in the brain, increasing synapses (connections) in the brain, and raising the number of neurons (neurogenesis) in the hippocampus. Thus, by raising abnormally low GCSF and GMCSF levels in the blood, the electromagnetic field indirectly induces physical changes in the brain that are beneficial for cognitive function. TEMT reduced the higher than normal baseline levels of GCSF and GMCSF present in some AD subjects, but the reduction was typically to normal or near-normal levels typical of older, unimpaired individuals.

[0032]

[0047] As a result, subjects with overactive immune systems, such as AD subjects, stand to benefit greatly from TEMT administration through reactivation or rejuvenation of the immune system to combat AD pathogenesis. Conversely, subjects with one of the many diseases / conditions characterized by an overactive immune system, such as the "cytokine storm" of COVID-19, can be relieved from this immune hyperactivity through TEMT administration and the resulting reduction in cytokine levels.

[0033]

[0048] It should be noted that among the eight cytokines that exhibit immune modulation by TEMT, this modulation was universally in the same direction. For example, AD subjects with higher than normal levels of these eight cytokines always responded to TEMT with reduced levels of all eight cytokines - and vice versa for subjects with lower than normal cytokine levels. Thus, the method (200) provides a generalized immune modulation toward normal levels, regardless of whether a given cytokine is pro-inflammatory or anti-inflammatory. This is a unique immune modulation response not exhibited by any other technique or drug.

[0034]

[0049] In yet another example of addressing imbalances in blood levels of various cytokines, the method (200) may be performed on the user's body using a peripheral electromagnetic therapy (PEMT) device employing an electromagnetic wave generator (FIG. 1, 108) and a cabled electromagnetic emitter (FIG. 1, 102) to generate an electromagnetic field and radiate the electromagnetic field treatment into the subject's body beneath the electromagnetic emitter (FIG. 1, 102). In one particular example, there may be one or multiple electromagnetic emitters (FIG. 1, 102) depending on the disease / symptom to be treated. As an example, a patient with severe COVID-19 psoriasis may require multiple electromagnetic emitters (FIG. 1, 102) positioned bilaterally on the neck, axial arm region, and lower chest to suppress the cytokine storm and lower lung field inflammation typical of severe COVID-19 infection. In this example, the neck and axial emitters affect major blood and lymphatic vessels in those body regions to reduce the high blood cytokine levels of the patient's cytokine storm, while the lower lung field emitters simultaneously reduce the high lung cytokine levels that cause pulmonary inflammation in COVID-19 infected patients.

[0035]

[0050] In all of the above examples and more applications of either TEMT or PEMT to address imbalances in blood levels of various cytokines, the following ranges of emitted electromagnetic wave parameters may be used: a.Electromagnetic frequency from 1MHz to 430GHz; b. A power level of 0.1 to 8 W / kg average specific absorption rate (SAR); c. Pulse repetition rate 1-300Hz; d.Duty cycle from 1% to 100% (continuous).

[0036]

[0051] Thus, described herein are methods of applying electromagnetic fields to alter cytokine levels in a subject, possibly by directly activating or suppressing cytokine release from immune cells (e.g., lymphocytes, conventional T (Tcon) cells, macrophages, and mast cells). Such methods may activate or suppress Treg cells, which regulate cytokine release from immune cells.

[0037]

[0052] 3 is a flow chart of a method (300) for normalizing or enhancing cytokine levels in the bloodstream of a subject, according to another example of the principles described herein. As described above, the method (300) may include positioning (block 301) an array of electromagnetic emitters (FIG. 1, 102) in proximity to the subject, and generating (block 302) an electromagnetic field, thereby causing the electromagnetic emitters (FIG. 1, 102) to radiate the electromagnetic field.

[0038]

[0053] The method may also include increasing blood levels of VEGF (Block 303). Vascular endothelial growth factor (VEGF) is a cytokine that supports the generation and adulthood maintenance of meningeal lymphatic vessels. Studies have shown that increasing blood levels of VEGF can directly enhance the size (diameter) of meningeal lymphatic vessels, thereby increasing lymphatic flow through these widened vessels. Thus, increasing blood levels of the cytokine VEGF can "indirectly" increase lymphatic flow through the meningeal sacs by inducing widening of the meningeal canals.

[0039]

[0054] In AD subjects with low blood VEGF levels, a single 1-hour TEMT session significantly increases blood VEGF levels. After 60 days of TEMT in the same AD subjects, the increase in aggregate VEGF levels is even greater. These results are consistent with TEMT-induced higher blood VEGF levels, which indirectly increase meningeal lymphatic flow, thereby enhancing clearance of toxic proteins (e.g., Aβ and tau) from the brain.

[0040]

[0055] Thus, increasing blood VEGF levels (block 303) may equally well be utilized by the use of a somatic or peripheral electromagnetic therapy (PEMT) device. The same or different electromagnetic emitters (FIG. 1, 102) may be positioned on the body surface to generate electromagnetic waves, which may generate subsequent electromagnetic field treatment projections into the subject's body below the electromagnetic emitter (FIG. 1, 102), such as the neck and axial regions, to affect the large vascular and lymphatic vessels in these body regions. There may be one or more electromagnetic emitters (FIG. 1, 102), depending on the disease / symptom requiring treatment.

[0041]

[0056] Electromagnetic wave-induced secretion of VEGF from circulating blood cells (eg, lymphocytes, mast cells) via TEMT or PEMT devices increases meningeal lymphatic flow, thereby enhancing the removal of toxic proteins from the brain via this route.

[0042]

[0057] In this example, the method (300) can also enhance the clearance of toxic proteins from the brain. In particular, the method (300) can include increasing the clearance of β-amyloid (Aβ) and tau isoforms along with other brain toxins and metabolites from the brain through increased meningeal lymph flow (block 304). That is, the two toxic proteins that are the root cause of AD, namely β-amyloid (Aβ) and tau, can be increased in clearance from the brain through this method. According to the method (300), these isoforms are continuously removed from the brain and therefore do not accumulate to self-aggregate toxic "oligomers" or insoluble deposits. In fact, it has been hypothesized that a dysfunction in the clearance of these two proteins is the primary reason why oligomers and insoluble forms accumulate in AD brains. Until recently, it was hypothesized that the only route for Aβ and tau to be cleared from the brain was through cerebrospinal fluid (CSF) and then transported into venous blood. However, it has been determined that the brain contains an extensive system of "meningeal" lymphatic vessels that reside within the dura mater at the brain's surface. These lymphatic vessels drain brain fluid into the cervical lymph nodes, which then drain lymph into large veins, thus clearing various toxins from the brain. Thus, these meningeal lymphatic vessels and their unidirectional lymphatic flow into the venous system represent a second route of toxic protein clearance from the brain. Thus, a method (300) that increases Aβ and tau clearance from the brain through the meningeal lymphatic vessels (block 304) is highly desirable.

[0043]

[0058] Thus, as illustrated and described above, electromagnetic fields emitted from various electromagnetic emitters on the head surface (FIG. 1, 102) can directly affect the meningeal lymphatic vessels of the brain and lymphocytes therein. Electromagnetic waves from brain surface emitters can act "indirectly" to enhance drainage / flow from the brain to the meningeal lymphatic vessels, leading to enhanced clearance of toxins from the brain. This promotes the removal of Aβ and tau from the brain.

[0044]

[0059] In view of the above, increasing the clearance of Aβ and tau isoforms along with other brain toxins and metabolites (block 304) can be achieved by applying an electromagnetic field to the human head through TEMT or to the human body through PEMT by electromagnetic emitters (FIG. 1, 102) positioned on the head surface or body surface, respectively.

[0045]

[0060] In doing so, it increases the removal of toxins (e.g. Aβ, tau) from the brain via enhanced meningeal lymphatic flow / drainage.

[0046]

[0061] In the above example and other applications of either TEMT or PEMT to eliminate Aβ and tau isoforms along with other brain toxins and metabolites, the following ranges of emitted electromagnetic wave parameters are possible: a.Electromagnetic frequency from 1MHz to 430GHz; b. A power level of 0.1 to 8 W / kg average specific absorption rate (SAR); c. Pulse repetition rate 1-300Hz; d.Duty cycle from 1% to 100% (continuous).

[0047]

[0062] 4 is a flow chart of a method (400) for modulating AD markers in the bloodstream of a subject, according to one example of the principles described herein. As described above, in this method (400), an array of electromagnetic emitters (FIG. 1, 102) is positioned in the vicinity of the subject (block 401) and an electromagnetic field is generated (block 402). This can be done as described above in connection with FIG. 3.

[0048]

[0063] According to the method (400), AD markers in blood can be modulated in the same direction as blood cytokines (block 403) by applying electromagnetic waves through an electromagnetic emitter (FIG. 1, 102). In particular, the present specification also describes a method for modulating blood levels of AD markers (e.g., t-tau, p-tau, Aβ1-40, Aβ1-42, oligomeric Aβ) and cytokines to change in the same direction. For example, it may be desirable for a treatment to induce (directly or indirectly) an increase in blood cytokine levels induced by the above-mentioned method (300) to induce higher levels of total tau (t-tau) in the blood, the majority of which is innocuous monomeric tau form. Alternatively, it is equally possible that the methodology-induced increase in blood t-tau induces an increase in a particular cytokine in the blood. Of course, both changes in AD markers and cytokines induced by this methodology can occur independently of each other. Therefore, a methodology that can modulate both cytokine and AD marker levels in the same direction can be valuable for the prevention or treatment of AD or other brain diseases / disorders.

[0049]

[0064] In view of the above, modulation of AD markers in blood may be performed by applying TEMT to the human head or PEMT to the human body through electromagnetic emitters (FIG. 1, 102) positioned on either the head or the surface of the body, respectively. Modulation of AD markers in blood (e.g., t-tau, Aβ1-42) (block 403) may be in the same direction as changes in blood cytokine levels.

[0050]

[0065] In the above examples and any other applications of the TEMT or PEMT methodology for modulating AD markers in blood (block 403), the following ranges of electromagnetic wave parameters that may be implemented by application are possible: a.Electromagnetic frequency from 1MHz to 430GHz; b. A power level of 0.1 to 8 W / kg average specific absorption rate (SAR); c. Pulse repetition rate 1-300Hz; d.Duty cycle from 1% to 100% (continuous).

[0051]

[0066] In some instances, the induced change in blood AD markers is indicative of a change in blood levels of a cytokine. In other instances, the induced change in blood cytokine levels is indicative of a change in blood levels of an AD marker. In yet other instances, the induced change in blood AD markers occurs independently of a change in blood levels of a cytokine.

[0052]

[0067] 5 is a flow chart of a method (500) for treating brain fog / cognitive impairment via electromagnetic therapy according to one example of the principles described herein. As described above, the method (500) includes positioning an array of electromagnetic emitters (FIG. 1, 102) in the vicinity of a subject (block 501) and generating an electromagnetic field (block 502). According to the method (500), cognitive impairment is reduced through reduction in inflammation and free radical levels by applying electromagnetic waves through the electromagnetic emitters to generate the electromagnetic field (FIG. 1, 102) (block 503).

[0053]

[0068] Such cognitive impairment / brain fog may result from any number of circumstances. For example, method (500) may prevent or treat cognitive impairment / brain fog that may occur after a subject has been on a ventilator and / or has been hyperoxia for an extended period of time (such as with severe COVID-19 virus infection) or after the use of general anesthesia in an operating room with or without the use of a heart-lung machine. That is, viral and bacterial infections may induce a sudden and powerful increase in the number of cytokines in the blood, resulting in high fever and pulmonary complications such as inflammation, pneumonia, and fibrosis. In these circumstances, such as those associated with COVID-19, hospitalization and subsequent ICU care may be necessary, which usually involves mechanical ventilation with high oxygen due to respiratory distress and low blood oxygen saturation. Unfortunately, mechanical ventilation may cause an increase in inflammatory cytokines in the blood in the case of lung hyperinflation. Hyperoxia (>50%) has also been shown to induce brain fog / cognitive impairment later on and may promote Alzheimer's disease - most likely through the generation of oxygen free radicals.

[0054]

[0069] In view of the above, induction of cognitive impairment may be addressed by a method (500) whereby application of TEMT to the human head or PEMT to the human body through electromagnetic emitters (FIG. 1, 102) positioned on either the head or body surface, respectively, may be employed either during or following artificial ventilation and / or oxygen therapy to minimize or eliminate cognitive impairment that may follow such treatment.

[0055]

[0070] The method (500) also reduces or eliminates cognitive dysfunction / brain fog / migraine headaches that may occur after surgery, after general anesthesia, and / or post-perfusion syndrome. That is, both surgery and anesthesia can have long-term effects on cognition at various times after surgery - hence the term "post-operative cognitive dysfunction" (POCD) is a complication following surgery with anesthesia in patients over 65 years of age, involving both memory impairment and reduced willpower. Unfortunately, elderly patients with POCD are three times more likely to suffer from permanent cognitive impairment or AD compared to elderly patients without POCD. Currently, there is no effective treatment to treat POCD. Furthermore, general anesthesia, especially in elderly people or those with pre-existing cognitive impairment, may lead to POCD, exacerbating underlying cognitive problems and progressing to AD. The use of cardiopulmonary bypass during surgery may also lead to post-perfusion syndrome, characterized by brain fog, dizziness, and recurrent migraines. There is clinical evidence of an overactive immune system following surgery, general anesthesia, and post-perfusion syndrome. For example, the severity of POCD correlates with blood cytokine levels, suggesting the involvement of inflammatory cytokines in POCD. Furthermore, there is growing evidence of "neuroinflammation" due to microglial activation in POCD.

[0056]

[0071] In the above applications of either TEMT or PEMT to reduce or eliminate post-operative cognitive impairment / brain fog that often occurs after a subject is on mechanical ventilation and / or is hyperoxia for an extended period of time, the following ranges of electromagnetic wave parameters can be emitted: a.Electromagnetic frequency from 1MHz to 430GHz; b. A power level of 0.1 to 8 W / kg average specific absorption rate (SAR); c. Pulse repetition rate 1-300Hz; d.Duty cycle from 1% to 100% (continuous).

[0057]

[0072] Since surgery in general, the use of anesthesia therein, and the use of cardiopulmonary bypass all involve an overactive immune system (high blood cytokine levels), the method may more specifically involve a) direct activation or inhibition of cytokine release from immune cells (e.g., lymphocytes, macrophages, adipocytes) or b) TEMT- or PEMT-induced reduction in blood cytokine levels (e.g., IL-17a, IL-18) through activation or inhibition of Treg cells which regulate cytokine release from immune cells.

[0058]

[0073] Because an overactive immune system is often seen following surgery, anesthesia, or bypass surgery, administration of electromagnetic therapy through any of the above methods can minimize or eliminate cognitive impairment induced by such procedures. In any of the examples of reducing cognitive impairment, the treatment methods may be used during hospitalization, simultaneously with or immediately following treatment in an ICU, or before, during, or after hospitalization or outpatient care, and may be used days, months, or years after general anesthesia or use of cardiopulmonary bypass.

[0059]

[0074] FIG. 6A shows a subject wearing a TEMT device (610), which is an example of a method for providing transcranial electromagnetic therapy (TEMT) to the head. The electromagnetic field is generated by an emitter in the head cap through a wired connection to a control box / battery combination worn on the arm. A cable containing eight wires connects this control box / battery to each of the eight electromagnetic emitters (FIG. 1, 102) located within the two-layer head cap. The TEMT device (610) allows for nearly complete mobility within the home, allowing the wearer to perform most home activities while receiving electromagnetic therapy. It can be adjusted to several power levels and does not emit sound. FIG. 6B shows the size and location of the eight electromagnetic emitters (102) encased between the two-layer head cap. For simplicity, a single electromagnetic emitter (102) is shown with a reference number. During any given treatment session, these eight electromagnetic emitters (102) can be activated sequentially, so that only one electromagnetic emitter (102) can be activated at any given time. Figure 6C shows a finite difference time domain (FTDT) computer simulation of the electric field (dark area in Figure 6C) generated by a single active electromagnetic emitter (102) set at 915 MHz frequency and 4.0 W / kg specific absorption rate (SAR). Given the distribution and penetration depth of the electric field from this one active electromagnetic emitter (102) into the temporal lobe of the brain, it can be seen that during any given treatment, all eight electromagnetic emitters (102) collectively provide a whole forebrain electromagnetic field treatment. There can be approximately 200 treatment cycles (emitter activations) per second, although this "pulse repetition rate" may be lower (e.g., 40 Hz) or higher (e.g., 250 Hz).

[0060]

[0075] FIG. 7A shows the major arterial vasculature in the human brain (below the brain's surface) and their proximity to the electromagnetic emitters (102) of the TEMT device (FIG. 6A, 610). The only barriers between these surface electromagnetic emitters (102) and the surface of the brain are hair, a thin layer of skin and connective tissue, the skull, a thin layer of dura mater, and the arachnoid cavity / pia mater. Given the distribution and penetration of the electromagnetic field emitted from one of the eight electromagnetic emitters (102) (at 915 MHz and 4.0 W / kg), it should be clear that the overall arrangement of the eight electromagnetic emitters (102) provides electromagnetic treatment to the deep vasculature of the entire forebrain in this example.

[0061]

[0076] Figure 7B shows the high density arterial blood vessels on the surface of the human brain and how close these blood vessels are to each of the eight electromagnetic emitters (102) of the TEMT device (Figure 6A, 610) on the human head. In view of the computer modeled electromagnetic fields emanating from each of the eight electromagnetic emitters (102) as shown in Figure 6C, it should be apparent to one skilled in the art that both deep and superficial vasculature of the human brain are subjected to a robust electromagnetic field.

[0062]

[0077] Figure 8A shows the graphed results of treating an Alzheimer's patient twice daily with the TEMT device (Figure 6A, 610) on blood levels of eight cytokines. As can be seen for all eight cytokines, where baseline blood levels were abnormally low (below the horizontal dotted normal level line), TEMT increased blood levels after 60 days of treatment (solid line). Conversely, where baseline cytokine levels were abnormally high, TEMT reduced blood levels after 60 days of treatment (dashed line).

[0063]

[0078] In both situations, TEMT increased or decreased plasma cytokine levels toward or to the average for elderly normal individuals (represented by the dotted horizontal line). Such information clearly demonstrates that TEMT and the methods described herein provide "immunomodulation" of these eight cytokines by returning them to normal or near normal, or in the case of treatment of an underactive immune system, by increasing cytokine levels above normal levels.

[0064]

[0079] The immunomodulatory role of TEMT on circulating cytokines is further illustrated by Figure 8B, which shows the mean and SEM of the individual subjects shown in Figure 8A for IL-17a and IL-18. As can be seen, TEMT induced both the initially low and initially high cytokine groups for both IL-17a and IL-18 to converge towards normal levels of these two cytokines in elderly individuals.

[0065]

[0080] Figure 9 shows the graphed results of treating an Atlheimer's patient with the TEMT device (Figure 6A, 610) on the blood levels of four cytokines after only a single 1-hour TEMT session. As can be seen for all four cytokines, if the baseline blood levels were abnormally low (below the horizontal dotted normal level line), 1 hour of TEMT increased the blood levels on day 1, immediately after TEMT (solid line). Conversely, if the baseline cytokine levels were abnormally high, 1 hour of TEMT decreased the blood levels on day 1, immediately after TEMT (dashed line).

[0066]

[0081] As with blood cytokines after 60 days of daily TEMT, consistent profiles are seen for all four graphed cytokines from the same AD subjects after only a single TEMT session (the remaining four cytokines showed similar results). For AD patients with abnormally low baseline plasma levels (solid lines), a single TEMT session increased cytokine levels to near-normal or slightly higher than normal values. For AD patients with abnormally high baseline levels of these cytokines, a single TEMT session reduced cytokine levels to normal or lower than normal values ​​in many cases (dashed lines). Thus, already after only one TEMT session, blood cytokine levels had a trend toward or were moving toward normal levels through either increased levels or by: As shown in FIG. 9, the methods described herein provide immune-modulating capabilities without long-term treatment, but can be achieved to a significant extent with acute treatment.

[0067]

[0082] FIG. 10 shows the meningeal lymphatic vessels of the human brain, located mostly on the brain surface within the dura mater. These lymphatic vessels have recently been discovered and are now considered to be a second pathway (in addition to CSF) for removing / clearing toxic substances (e.g., Aβ, tau) from the brain. Lymph in these meningeal lymphatic vessels flows unidirectionally from the neck into the deep cervical lymph nodes and finally into the large veins that supply the heart. Meningeal lymphatic vessels have been targeted for AD treatment because increasing their lymph flow would remove more toxic Aβ and tau soluble aggregates from the brain. Greater lymph flow in these lymphatic vessels would likely enhance the clearance of brain toxins.

[0068]

[0083] The cytokine VEGF is a factor necessary for the generation and maintenance of meningeal lymphatic vessels during adulthood. This cytokine has the ability to widen meningeal lymphatic vessels and increase lymphatic flow. As shown by the use of a TEMT device (FIG. 6A, 610) in AD subjects, the production / release of VEGF by immune cells (e.g., lymphocytes) in the blood is significantly enhanced in AD subjects with low VEGF levels. Thus, these subjects are expected to have increased meningeal lymphatic flow and, consequently, increased brain clearance of Aβ and tau aggregates as a result of TEMT. Indeed, increased levels of soluble Aβ and t-tau are found in the plasma of AD patients after 60 days of TEMT.

[0069]

[0084] FIG. 11A shows the lymphatic system within the upper half of the human body. It can be seen that lymph from the head drains through the cervical lymph nodes, and lymph returning from the arms and immediate chest area drains through the axillary lymph nodes in the axial region of the arms. Lymph from the brain drains through the meningeal lymphatics of the brain to the deep cervical lymph nodes in the neck and into the large veins that feed into the heart. Lymph from the arms and immediate chest area drains through the axillary lymph nodes in the axial region of the arms before joining the thoracic duct.

[0070]

[0085] Figure 11B shows the major arteries and veins in the upper body. Figure 11B illustrates a method of providing peripheral electromagnetic therapy (PEMT) using electromagnetic emitters (102) positioned over the major arteries, veins, and lymphatic vessels, particularly in the axial region of the neck and arms. It can be seen that blood WBCs and lymphatic WBCs in these major vessels can be easily affected by electromagnetic therapy from these body surface electromagnetic emitters (102).

[0071]

[0086] From Figures 11A and 11B, it is clear that the two upper body regions contain the major arteries, veins, and lymphatic vessels and are the axial regions of the neck and arms. Therefore, if one wishes to affect the WBCs and their cytokine secretion, the electromagnetic emitters (102) can be placed in these two upper body sites. Thus, Figure 11B shows a method of providing peripheral (body) electromagnetic therapy (PEMT) using left and right electromagnetic emitters (102) positioned as shown, placed in these two body regions. As a result, it can be seen that the WBCs (e.g., lymphocytes) in the blood and lymph under these emitters are most easily and robustly affected.

[0072]

[0087] FIG. 12A shows the graphed results of measuring plasma t-tau levels in the same baseline and day 60 blood samples from AD subjects as in FIGS. 8A and 8B.

[0073]

[0088] From Figure 12A, it is clear that the t-tau response of these AD subjects to TEMT has the same full-wave profile as observed with the cytokines in Figures 8A and 8B. This is especially true for AD subjects with low blood t-tau levels at baseline.

[0074]

[0089] As is readily apparent, the same pattern of TEMT effects shown by blood cytokines was also present in TEMT effects on blood t-tau levels. With one exception, low blood t-tau levels at baseline lead to increased t-tau levels after TEMT (FIG. 12A, solid line). Since soluble t-tau is almost entirely monomeric tau, this increase may reflect a treatment-induced increase in monomeric t-tau in plasma, which is consistent with disaggregation of oligomeric tau in plasma. If baseline t-tau levels were high at baseline, there was a small decrease in t-tau after TEMT (dashed line). This may be a positive effect in maintaining high soluble (monomeric) t-tau. FIG. 12B shows the same data as FIG. 12A, but the means and SEM of the two groups are presented rather than data from individual subjects. These t-tau results suggest that there are parallel effects of TEMT on cytokines and t-tau.

[0075]

[0090] The foregoing description has been presented only to illustrate and describe the invention. It is not intended to be exhaustive or to limit the invention to any precise form disclosed. Many modifications and variations are possible in light of the above teachings.

[0076]

[0091] The examples set forth herein have been chosen and described in order to best explain the principles of the teachings and their practical application, the foregoing description being intended to enable others skilled in the art to best utilize the teachings in various embodiments and with various modifications as may be appropriate for the particular uses contemplated.

Claims

1. 1. A transcranial electromagnetic therapy (TEMT) or peripheral electromagnetic therapy (PEMT) device for normalizing cytokine levels in the bloodstream of a subject, comprising: an array of electromagnetic emitters configured to provide transcranial electromagnetic therapy (TEMT) or peripheral electromagnetic therapy (PEMT) while positioned proximate to the subject; an electromagnetic wave generator for generating an electromagnetic field; With An apparatus configured to normalize cytokine levels in the bloodstream of the subject by applying the electromagnetic field to the subject through the electromagnetic emitter.

2. 10. The device of claim 1, wherein cytokine levels are normalized in blood vessels, lymph vessels, and brain tissue beneath the emitter.

3. The apparatus of claim 1 , wherein the array of electromagnetic emitters is positioned adjacent to a head surface of the subject.

4. The apparatus of claim 1 , wherein the array of electromagnetic emitters is positioned adjacent to a body surface of the subject.

5. The method of claim 1 , wherein normalizing cytokine levels comprises activating or suppressing cytokine release from at least one immune cell.

6. The method of claim 1 , wherein normalizing cytokine levels comprises increasing cytokine levels if the initial cytokine levels are low.

7. The method of claim 1 , wherein normalizing cytokine levels comprises lowering cytokine levels if the initial cytokine levels are high.

8. 2. The device of claim 1, wherein normalizing cytokine levels comprises enhancing secretion of granulocyte colony stimulating factor (GCSF) cytokines and granulocyte macrophage colony stimulating factor (GMCSF) cytokines from circulating white blood cells.

9. The device of claim 1 , wherein the electromagnetic emitters are positioned on brain glial cells and brain blood vessels.

10. The electromagnetic waves of the electromagnetic field are Frequencies from 1 megahertz (MHz) to 430 gigahertz (GHz), Power levels between 0.1 and 8 Watts / kilogram (W / kg) average Specific Absorption Rate (SAR); A pulse repetition rate of 1 to 300 Hertz (Hz), and 1% to 100% duty cycle The apparatus of claim 1 , further comprising:

11. 10. The apparatus of claim 1, wherein normalizing cytokine levels in the bloodstream of the subject by applying electromagnetic treatment to the subject through the electromagnetic emitter comprises periodic treatment at predetermined intervals.

12. 10. The apparatus of claim 1, wherein normalizing cytokine levels in the bloodstream of the subject by applying electromagnetic therapy to the subject through the electromagnetic emitter treats an immune dysfunction characterized by abnormal blood cytokine levels.

13. 2. The device of claim 1, further comprising enhancing clearance / elimination of amyloid beta (Aβ) and tau isoforms, along with other brain toxins and metabolites, from the brain by applying electromagnetic therapy to the subject through the electromagnetic emitter.

14. 10. The device of claim 1, further comprising increasing blood levels of vascular endothelial growth factor (VEGF) cytokines to indirectly induce dilation of the meningeal canals, thereby increasing lymphatic flow through the meningeal canals.

15. 10. The device of claim 1, further comprising modulating Alzheimer's Disease (AD) markers in the blood in the same direction as cytokine levels by applying electromagnetic therapy to the subject through the electromagnetic emitter.

Citation Information

Patent Citations

  • Systems and methods for driving neural activity to control brain signaling and gene expression

    WO2019173847A1